An innovative liver cancer therapy developed by an associate of China Grand Pharmaceutical (00512.HK) has successfully completed its US clinical trial, meeting its primary endpoint.
In an announcement, the company stated that SIR-Spheres, an yttrium-90 microsphere injection developed by its associate Sirtex Medical Pty Ltd, concluded its study for treating unresectable hepatocellular carcinoma. The successful outcome marks a significant milestone for the product, which is branded as E-Gan-Tai.
The therapy is a form of selective internal radiation therapy (SIRT) that delivers high doses of radiation directly to liver tumors. Hepatocellular carcinoma is the most common type of primary liver cancer, and unresectable cases present a significant treatment challenge, creating a substantial market opportunity for new, effective therapies. While specific efficacy and safety data from the trial were not disclosed, meeting the clinical endpoint is a crucial de-risking event.
For China Grand Pharmaceutical, the positive results validate its investment in the oncology space and position Sirtex for a potential regulatory filing in the United States. The news provides a significant boost to the company's pipeline, potentially opening up a new revenue stream pending regulatory approval and commercial launch.
The successful trial completion is a critical step for bringing E-Gan-Tai to American patients. The treatment offers a minimally invasive procedure for patients with liver tumors that cannot be surgically removed.
This positive clinical development is a key catalyst for China Grand Pharmaceutical. Investors will now watch for the timing of a New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) and any subsequent regulatory milestones.
This article is for informational purposes only and does not constitute investment advice.
